申请人:Point Biopharma, Inc.
公开号:US11129912B1
公开(公告)日:2021-09-28
The radiopharmaceutical 177Lu-PSMA I&T is provided, including in high purities with extended shelf life. Further provided are methods of synthesis of 177Lu-PSMA I&T and pharmaceutical compositions and methods of treatment that comprise 177Lu-PSMA I&T.
提供了放射性药物 177Lu-PSMA-I&T,包括高纯度和延长保质期的 177Lu-PSMA-I&T。此外,还提供了 177Lu-PSMA I&T 的合成方法以及包含 177Lu-PSMA I&T 的药物组合物和治疗方法。